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Abstract 
Background: Diabetic retinopathy has a significant impact in every healthcare system. Despite that fact, there are 
few accurate estimates in the prevalence of DR in Brazil’s different geographic regions, particularly proliferative DR and 
diabetic macular edema. This study aims to determine the prevalence of diabetic retinopathy in Brazil’s five continen-
tal regions and its determinant factors.
Methods: This multi center, cross-sectional, observational study, conducted between August 2011 and December 
2014, included patients with type 1 diabetes from the 5 Brazilian geographic regions (South, Southeast, North, North-
east and Midwest). During a clinical visit, a structured questionnaire was applied, blood sampling was collected and 
each patient underwent mydriatic binocular indirect ophthalmoscopy evaluation.
Results: Data was obtained from 1644 patients, aged 30.2 ± 12 years (56.1% female, 54.4% Caucasian), with a 
diabetes duration of 15.5 ± 9.3 years. The prevalence of diabetic retinopathy was 242 (36.1%) in the Southeast, 102 
(42.9%) in the South, 183 (29.9%) in the North and Northeast and 54 (41.7%) in the Midwest. Multinomial regression 
showed no difference in the prevalence of non-proliferative diabetic retinopathy in each geographic region, although, 
prevalence of proliferative diabetic retinopathy (p = 0.022), and diabetic macular edema (p = 0.003) was higher in the 
Midwest. Stepwise analyses reviled duration of diabetes, level of HbA1c and hypertension as independent variables.
Conclusions: The prevalence of non proliferative diabetic retinopathy in patients with type 1 diabetes was no dif-
ferent between each geographic region of Brazil. The Midwest presented higher prevalence of proliferative diabetic 
retinopathy and diabetic macular edema. Duration of DM and glycemic control is of central importance to all. Hyper-
tension is another fundamental factor to every region, at special in the South and Southeast. Glycemic control and 
patients in social and economic vulnerability deserves special attention in the North and Northeast of Brazil.
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Background
Diabetic retinopathy (DR) has a significant impact in the 
health care system. It is the leading cause of blindness 
among working-aged adults worldwide [1]. From 1990 to 
2010, DR ranked as the fifth most common cause of pre-
ventable blindness and fifth most common cause of mod-
erate to severe visual impairment [2, 3]. As a major public 
health problem causes productivity losses due to early 
retirement, suffering and diminishing quality of life, for 
millions of people. Vision disability is one of the top 10 
disabilities among adults [4]. In Brazil, early retirement 
in patients due to diabetes-related chronic complications 
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may result in more than 15  years of workforce loss per 
retired patient [5].
The increasing incidence of type 1 diabetes is a chal-
lenge for health care systems in many countries. Type 
1 diabetes (T1D) is increasing by around 3% every year, 
particularly among children. Around 86,000 children 
develop type 1 diabetes each year and Brazil ranks as the 
third country in the world in number of children with 
T1D [6].
Despite the significance of this problem, [7], there are 
few accurate estimates of DR prevalence in Brazil, and 
even less in it’s different geographic regions, particularly 
severe vision-threatening stages of the disease, includ-
ing proliferative DR (PDR) and diabetic macular edema 
(DME).
Brazil with its continental territory is the fifth largest 
country in the world, and the largest country of South 
America. Has an estimated population of 204.4 million 
people with 85.43% living in urban areas [8]. Brazil has 
diverse social, economic and educational realities as well 
as unequal access to public health care and education 
system. Generating a broader and more precise estimate 
of the prevalence of DR in each of the five regions of Bra-
zil and its relationship with major modifiable risk factors 
is crucial for guiding specific public health education and 
optimal clinical management of diabetes. We therefore 
conducted a multi center study in Brazil to determine 
the prevalence of DR and its sight-threatening end points 
(PDR and DME) throughout its five continental regions 
and the determinants factors for each region.
Methods
Patients
This multi center, cross-sectional, observational study, 
conducted between August 2011 and December 2014, 
included patients with T1D from 14 public secondary 
(ambulatory out-patient clinics) and tertiary care-level 
clinics (ambulatory outpatient clinics in university hospi-
tals) located in 10 different cities of the 5 Brazilian geo-
graphic regions (South, Southeast, North, Northeast and 
Midwest). Inclusion criterion was T1D according to the 
American Diabetes Association (ADA) [9]. Diagnosis was 
based on the typical clinical presentation, including vari-
able degrees of weight loss, polyuria, polydipsia and poly-
phagia, and the need for continuous insulin use since the 
diagnosis of T1D. Antibody dosage was not done because 
of it’s limited availability in our public healthcare system. 
Exclusion criteria were pregnancy, lactation, recent his-
tory of acute infection or diabetic ketoacidosis 3 months 
preceding evaluation. All patients received healthcare 
from the Brazilian National Health Care System (Sistema 
Único de Saúde, SUS), that guarantees free healthcare 
for every Brazilian citizen. All eligible participating cent-
ers had a diabetes clinic with at least one endocrinologist 
which provided data from a minimum of 50 outpatients 
with diagnosis of T1D who regularly attended the clinic.
The local ethics committee approved the study pro-
tocol (CAAE: 0214.0.228.000-10) and written informed 
consent was obtained from all patients or their legal 
representative.
Data collection
During a clinical visit, a structured questionnaire applied 
by trained physician accessed demographic data, clinical 
history, educational and economic status for each patient 
enrolled. The following variables were assessed during 
the interview: age, age at diagnosis, duration of diabe-
tes, ethnicity, height (m), weight (kg), smoking status, 
self reported level of physical activity, level of education 
and economic status, previews diagnose and treatment 
of ophthalmological pathologies. Blood sampling was 
collected for determination of HbA1c levels (by high-
performance liquid chromatography—HPLC, Bio-Rad 
Laboratories, Hercules, California, USA). Body mass 
index (BMI) was determined by dividing an individual’s 
weight (kg) by the square of their height  (m2). Economic 
status was defined according to the Brazilian Economic 
Classification Criteria [10]. The following economic sta-
tus categories were considered for this analysis: high, 
middle, low, and very low. All patients were referred 
for fundoscopy evaluation. To standardize procedure 
and evaluation, retina specialist from each center were 
assembled at one University center before the beginning 
of the study.
Each patient had both eyes examined and underwent 
mydriatic binocular indirect ophthalmoscopy. Mydria-
sis was obtained with 1% tropicamide drops. Binocular 
indirect ophthalmoscopy was performed with an Eyetec 
Ophthalmoscope (Eyetec, São Carlos-SP, Brazil) and a 
20-diopter lens (Volk Optical, Mentor, OH, USA) by an 
experienced retinal specialist in each center. Each eye 
was classified for DR and DME according to the Ameri-
can Academy of Ophthalmology guidelines [11]. In brief, 
non-proliferative DR (NPDR) was graded into mild, 
when micro aneurysms or dot hemorrhages was found, 
moderate when more than mild and less then severe, and 
severe if hemorrhages (> 20) in four quadrants or venous 
beadings in two quadrants or intraretinal microvascu-
lar abnormalities in one quadrant was found. PDR was 
defined as disc neovascularization or elsewhere, vitre-
ous hemorrhages or tractional retinal detachment. For 
patient classification, DR severity in the worst eye was 
considered.
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Sample calculation
The sample size of the present study was based on the 
Brazilian Multi center Type 1 Diabetes Study, described 
elsewhere [12]. The number of patients needed to be 
enrolled in each region was calculated based on the esti-
mated prevalence of T1D and DR in Brazil [13] combined 
with the overall population density of each geographic 
region reported in the 2000 Brazilian Institute of Geog-
raphy and Statistics Census (IBGE) (38.8, 2.6, 29.0, 23.0 
and 6.6% in the Southeast, North, Northeast, South and 
Midwest regions, respectively) [14]. Because of the small 
number of patients needed to be enrolled at the North 
of Brazil, for statistical analysis, data from the North and 
Northeast regions were combined.
Statistics
Statistical analyses were performed with SPSS 19.0 for 
Windows (SPSS Inc., Chicago, IL, USA). Data are pre-
sented as mean and standard deviation for continuous 
variable. Categorical variables are presented as absolute 
and relative frequency.
Comparisons between categorical variables were per-
formed using exact Fisher test, where association was 
present Standard Residual was used to identify excess. 
Standard Residual (S.Res.) has normal distribution and 
is considered significant when absolute values are greater 
than 1.96. Positive values are considered excess, there are 
more cases than expected. Kruskal–Wallis (more than 
two groups) or Wilcoxon Test (two groups) were used for 
comparison between quantitative variables. When sig-
nificant at the Kruskal–Wallis test multiple analyses were 
performed using the Wilcoxon test and Bonferroni cor-
rection. Linear model was used for further analyses with 
dependent variable being retinopathy classification group 
and independent variables the geographic regions and all 
of those with statistical significance or clinical relevance 
according to literature: age, sex, ethnicity, level of educa-
tion, economic status, duration of diabetes, HbA1c, BMI, 
level of exercise, smoking, hypertension, hypercholes-
terolemia and level of care. Stepwise multiple regression 
analysis was further used for reduced model with the 
most important variables related with the disease. Level 
of significance was considered 5%.
Results
Overview of demographic and clinical data
Our study enrolled 1760 patients distributed in all five 
regions of Brazil, those of which 1644 underwent fun-
doscopy evaluation. Clinical and demographic data 
from the study population are shown in Table  1. Over-
all, 987 (56.1%) were females, with a duration of diabe-
tes of 15.5 ± 9.3  years. Mean age was 30.2 ± 12  years 
and 958 (54.4%) were Caucasian. The tertiary health 
care accounted for 63.0% of the patients enrolled. Level 
of education was measured as years of study, which the 
mean was 12.2 ± 3.8 years. About half of the patients 910 
(51.7%) were physically active and 227 (13.8%) reported 
smoking. Mean HbA1c was 9.0 ± 2.1%. Dyslipidemia 
was present in 21.3% of the patients and hypertension in 
17.7%.
Overview of ophthalmological data
Considering each geographic region, Table 2, the preva-
lence of DR was 242 (36.1%) in the Southeast, 102 (42.9%) 
in the South, 183 (29.9%) in the North and Northeast 
and 53 (41.7%) in the Midwest. In the North and North-
east of Brazil, prevalence of DR was significantly lower, 
p = 0.015. Prevalence of mild, moderate and severe 
NPDR was statistically similar in each geographic region 
of Brazil, varying from: 129 (19.2%) in the Southeast to 
Table 1 Clinic and demographic data of the study popula-
tion
Data are presented as the means (SD) and n (%)
F female
a African-Brazilians, Mulattos, Asians, Native Indian
Variables
Age, years 30.2 ± 11
Gender, F (%) 987 (56.1%)
Duration of diabetes, years 15.5 ± 9.3
Ethnicity, n (%)
 Caucasian 958 (54.4%)
 Non-Caucasiana 802 (45.6%)
 Level of education, years 12.2 ± 3.8
Economic status
 High 53 (3%)
 Medium 801 (45.5%)
 Low 849 (48.2%)
 Very low 57 (3.2%)
Geographic region (%)
 Southeast 829 (47.1%)
 South 233 (13.2%)
 North and Northeast 490 (27.8%)
 Midwest 208 (11.8%)
Level of care, n (%)
 Secondary 651 (37%)
 Tertiary 1109 (63%)
Physical activity
 Yes 910 (51.7%)
 No 848 (48.2%)
Smoking
 Yes 227 (13.8%)
 No 1414 (86.2%)
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87 (14.2%) in the North and Northeast, 44 (6.6%) in the 
Southeast to 7 (5.5%) in the Midwest and 5 (0.8%) in 
the North and Northeast to 0 (0.0%) in the Midwest, 
respectively. The South had greater prevalence of PDR, 
[36 (15.1%) vs 17 (13.4%) in the Midwest, 64 (9.5%) in 
the southeast and 52 (8.5%) in the North and North-
east, p = 0.015]. In the matter of DME, prevalence in 
the Midwest region was higher [9 (7.1%) vs 17 (2.5%) in 
the Southeast, 3 (1.3%) in the South and 10 (1.6%) in the 
North and Northeast, p = 0.007].
When questioned on ophthalmological pathologies and 
treatments, 109 (6.2%) referred cataract and 59 (3.4%) 
glaucoma. Prevalence of cataract and glaucoma was no 
different in each region of Brazil.
Analysis of variables related to DR by geographic regions
Regions overview
Analysis of variables related to DR by geographic regions 
are shown in Tables 2, 3.
As expected, duration of DM was directly related to 
severity of DR in all regions of Brazil, p = 0.000. Mean 
duration of DM was higher in the South and Southeast 
(17.6 ± 9.9 and 17.0 ± 9.7  years, respectively) and lower 
in the North and Northeast of Brazil (12.6 ± 7.7  years). 
Table 2 Clinic, demographic and laboratory data according to geographic regions
Data are presented as the mean (SD) and N (%)
BMI body mass index, DR diabetic retinopathy, NPDR non-proliferative diabetic retinopathy, DME diabetic macular edema
* p < 0.001 vs every other region. ** p < 0.000 vs Southeast and South. *** p < 0.000 vs North and Northeast and Midwest. +p = 0.003 vs North and Northeast. 
++p < 0.049 vs Southeast and North and Northeast
# Standard Residual 2.8 ## Standard Residual 5.6 ### Standard Residual 2.3
a Standard Residual 2.6, b Standard Residual 5.3, c Standard Residual 4.2, d Standard Residual > 6.1, e Standard Residual 3.4, f Standard Residual 3.9
Variables Southeast South North and Northeast Midwest p value
Age, years 31.0 ± 12.3 34.4 ± 12.8* 26.8 ± 9.8** 29.0 ± 11.7 0.000
Duration of diabetes, years 17.0 ± 9.7*** 17.6 ± 9.9*** 12.6 ± 7.7 14.1 ± 8.7 0.000
Level of HbA1c (%) 8.8 ± 2.0+ 9.1 ± 2.1 9.3 ± 2.3 9.2 ± 2.1 0.003
Level of education, years 12.0 ± 3.5 12.0 ± 4.0 12.2 ± 4.0 13.2 ± 4.3++ 0.004
BMI 24.5 ± 4.4 24.6 ± 3.8 23.5 ± 3.6** 23.9 ± 4.4 0.000
Physical activity, n (%)
 Yes 163 (38.1%) 60 (14%) 179 (41.8%)# 26 (6.1%) 0.039
 No 577 (43.4%) 193 (14.5%) 457 (34.3%) 104 (7.8%)
Smoking, n (%)
 Yes 97 (39.4%) 66 (26.8%)## 71 (28.9%) 12 (4.9%) 0.000
 No 644 (42.5%) 187 (12.4%) 565 (37.3%)a 118 (7.8%)
Hypertension
 Yes 137 (18.5%) 68 (26.9%)c 78 (12.3%) 23 (17.6%) 0.000
 No 604 (81.5%) 185 (73.1%) 556 (87.7%)c 108 (82.4%)
Hypercholesterolemia
 Yes 182 (24.7%)e 60 (23.7%) 100 (15.8%) 24 (18.5%) 0.001
 No 556 (75.3%) 193 (76.3%) 533 (84.2%)f 106 (81.5%)
Economic status, n (%)
 High 14 (1.9%) 7 (2.8%) 23 (3.6%) 8 (6.2%)### 0.000
 Medium 380 (51.3%)b 142 (56.1%)c 188 (29.6%) 63 (48.5%)
 Low 335 (45.2%) 100 (39.5%) 375 (59.1%)d 58 (44.6%)
 Very low 12 (1.6%) 4 (1.6%) 49 (7.7%)d 1 (0.8%)
Retinopathy stage
 DR absent 429 (63.9%) 136 (57.1%) 430 (70.1%)e 74 (58.3%) 0.015
 Mild NPDR 129 (19.2%) 45 (18.9%) 87 (14.2%) 29 (22.8%)
 Moderate NPDR 44 (6.6%) 20 (8.4%) 39 (6.4%) 7 (5.5%)
 Sever NPDR 5 (0.7%) 1 (0.4%) 5 (0.8%) 0 (0.0%)
 Proliferative DR 64 (9.5%) 36 (15.1%)a 52 (8.5%) 17 (13.4%)
 DME 17 (2.5%) 3 (1.3%) 10 (1.6%) 9 (7.1%)f 0.007
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Table 3 Clinic, demographic and laboratory data by diabetic retinopathy classification according to geographic region
Variables DR absent Mild NPDR Moderate NPDR Sever NPDR Proliferative DR p value
Duration of diabetes, years
Mean (SD)
 Southeast 14.2 ± 8.6* 19.0 ± 9.6** 22.3 ± 8.7 22.8 ± 7.8 25.7 ± 9.5 0.000
 South 14.1 ± 9.3## 20.5 ± 9.5 19.8 ± 6.1 19.0 ± 0.0 25.7 ± 8.5
 North and Northeast 10.7 ± 6.8+ 15.9 ± 7.3 15.5 ± 9.0** 15.3 ± 8.7 20.0 ± 7.9
 Midwest 10.0 ± 6.6* 17.3 ± 7.1** 22.0 ± 6.8 – 23.6 ± 9.2
Level of HbA1c (%)
Mean (SD)
 Southeast 8.7 ± 2.0*** 9.3 ± 2.2 9.5 ± 2.6 8.4 ± 1.1 8.6 ± 1.4 0.012
 South 8.8 ± 1.9 9.4 ± 2.1 10.0 ± 3.5 10.4 ± 0.0 8.9 ± 1.6 0.388
 North and Northeast 9.0 ± 2.1### 9.1 ± 2.3### 11.1 ± 2.5 10.9 ± 3.6 9.5 ± 2.5 0.002
 Midwest 9.1 ± 2.2 9.0 ± 2.1 9.5 ± 1.5 – 8.9 ± 1.8 0.698
Level of education, years
Mean (SD)
 Southeast 12.1 ± 3.3 11.8 ± 3.9 12.1 ± 3.8 11.5 ± 1.9 11.9 ± 3.8 0.850
 South 12.3 ± 3.6 12.3 ± 4.2 10.5 ± 3.8 13.0 ± 0.0 11.7 ± 5.1 0.307
 North and Northeast 12.7 ± 3.9### 11.7 ± 4.1 10.0 ± 3.7 13.3 ± 4.6 11.2 ± 4.0 0.003
 Midwest 13.1 ± 3.5 13.7 ± 5.3 12.3 ± 6.7 – 13.6 ± 4.7 0.736
BMI
Mean (SD)
 Southeast 24.0 ± 3.9# 25.1 ± 4.9 26.3 ± 4.9 23.0 ± 6.3 26.3 ± 6.1 0.002
 South 23.9 ± 4.0++ 26.0 ± 2.8 24.5 ± 4.2 24.9 ± 0.0 25.1 ± 3.7 0.006
 North and Northeast 23.3 ± 3.4 24.4 ± 4.2 24.9 ± 4.1 22.8 ± 1.3 23.0 ± 3.8 0.075
 Midwest 23.1 ± 4.2** 24.7 ± 5.1 24.4 ± 3.4 – 25.8 ± 4.5 0.010
Level of care, n (%)
 Southeast
  Secondary 77 (70.6%) 18 (16.5%) 12 (11.0%)a 2 (1.8%) 0 (0.0%) 0.000
  Tertiary 352 (62.5%) 111 (19.7%) 32 (5.7%) 4 (0.7%) 64 (11.4%)d
 South
  Secondary 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
  Tertiary 136 (57.1%) 45 (18.9%) 20 (8.4%) 1 (0.4%) 36 (15.1%)
 North and Northeast 0.000
  Secondary 254 (63.0%) 69 (17.1%)c 29 (7.2%) 3 (0.7%) 48 (11.9%)f
  Tertiary 175 (83.3%)e 18 (8.6%) 10 (4.8%) 3 (1.4%) 4 (1.9%)
 Midwest
  Secondary 74 (58.3%) 29 (22.8%) 7 (5.5%) – 17 (13.4%)
  Tertiary 0 (0.0%) 0 (0.0%) 0 (0.0%) – 0 (0.0%)
Physical activity, n (%)
 Southeast
  Yes 96 (62.7%) 30 (19.6%) 13 (8.5%) 2 (1.3%) 12 (7.8%) 0.627
  No 333 (64.2%) 98 (18.9%) 31 (6.0%) 4 (0.8%) 53 (10.2%)
 South
  Yes 26 (44.8%) 11 (18.9%) 9 (15.5%) 0 (0.0%) 12 (20.7%) 0.066
  No 110 (61.1%) 34 (19.0%) 11 (6.1%) 1 (0.6%) 24 (13.3%)
 North and Northeast
  Yes 132 (74.6%) 26 (14.7%) 9 (5.1%) 1 (0.6%) 9 (5.1%) 0.278
  No 297 (68.3%) 61 (14.0%) 30 (6.9%) 4 (0.9%) 43 (9.9%)
 Midwest
  Yes 13 (50.0%) 8 (30.8%) 1 (3.8%) – 4 (15.4%) 0.658
  No 61 (60.4%) 21 (20.8%) 6 (5.9%) – 13 (12.9%)
Page 6 of 11Drummond et al. Diabetol Metab Syndr  (2018) 10:17 
Data are presented as the means (SD) and N (%)
DR diabetic retinopathy, NPDR non-proliferative diabetic retinopathy, BMI body mass index
* p < 0.006 vs every other DR, ** p < 0.004 vs proliferative DR, *** p < 0.023 vs mild NPDR, #p = 0.032 vs moderate NPDR, ## p < 0.004 vs mild NPDR and proliferative DR, 
###p < 0.005 vs moderate NPDR, +p<0.003 vs mild and moderate NPDR and proliferative DR. ++ p < 0.004 vs mild NPDR
a Standard Residual 2.2, b Standard Residual 3.0, c Standard Residual 3.1, d Standard Residual 3.7, e Standard Residual 5.2, f Standard Residual 4.2, g Standard Residual 
3.9, h Standard Residual 8.3, i Standard Residual 4.9, j Standard Residual 5.9, k Standard Residual 7.4
Table 3 continued
Variables DR absent Mild NPDR Moderate NPDR Sever NPDR Proliferative DR p value
Smoking, n (%)
 Southeast
  Yes 51 (50.0%) 25 (24.5%) 8 (7.8%) 2 (2.0%) 16 (15.7%)a 0.048
  No 429 (66.1%)c 119 (18.3%) 41 (6.3%) 4 (0.6%) 56 (8.6%)
 South
  Yes 26 (45.6%) 10 (17.5%) 9 (15.8%)a 0 (0.0%) 12 (21.1%) 0.049
  No 99 (61.5%)a 31 (19.3%) 9 (5.6%) 1 (0.6%) 21 (13.0%)
 North and Northeast
  Yes 34 (68.0%) 5 (10.0%) 4 (8.0%) 1 (2.0%) 6 (12.0%) 0.425
  No 297 (70.4%) 62 (14.7%) 26 (6.2%) 3 (0.7%) 34 (8.1%)
 Midwest
  Yes 9 (47.4%) 6 (31.6%) 2 (10.5%) – 2 (10.5%) 0.405
  No 110 (59.8. %) 40 (21.7%) 9 (4.9%) – 25 (13.6%)
Hypercholesterolemia, n (%)
 Southeast
  Yes 99 (52.1%) 43 (22.6%) 23 (12.1%)d 2 (1.1%) 23 (12.1%) 0.000
  No 380 (68.0%)g 100 (17.9%) 26 (4.7%) 4 (0.7%) 49 (8.8%)
 South
  Yes 23 (46.9%) 6 (12.2%) 5 (10.2%) 1 (2.0%) 14 (28.6%)b 0.009
  No 102 (60.4%) 35 (20.7%) 13 (7.7%) 0 (0.0%) 19 (11.2%)
 North and Northeast
  Yes 32 (43.2%) 16 (21.6%)a 9 (12.2%)a 2 (2.7%) 15 (20.3%)g 0.000
  No 297 (75.0%)e 51 (12.9%) 21 (5.3%) 2 (0.5%) 25 (6.3%)
 Midwest
  Yes 17 (44.7%) 10 (26.3%) 3 (7.9%) – 8 (21.1%) 0.176
  No 102 (61.8%) 36 (21.8%) 8 (4.8%) – 19 (11.5%)
Hypertension, n (%)
 Southeast
  Yes 47 (33.6%) 37 (26.4%)a 22 (15.7%)i 2 (1.4%) 32 (22.9%)j 0.000
  No 433 (70.9%)h 107 (17.5%) 27 (4.4%) 4 (0.7%) 40 (6.5%)
 South
  Yes 19 (33.3%) 11 (19.3%) 7 (12.3%) 1 (1.8%) 19 (33.3%)f 0.000
  No 106 (65.8%)f 30 (18.6%) 11 (6.8%) 0 (0.0%) 14 (8.7%)
 North and Northeast
  Yes 16 (28.1%) 17 (29.8%)d 8 (14.0%) 0 (0.0%) 16 (28.1%)e 0.000
  No 313 (75.8%)k 50 (12.1%) 22 (5.3%) 4 (1.0%) 24 (5.8%)
 Midwest
  Yes 9 (26.5%) 10 (29.4%) 4 (11.8%) – 11 (32.4%)d 0.000
  No 110 (65.1%)f 36 (21.3%) 7 (4.1%) – 16 (9.5%)
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On the other hand, levels of HbA1c were greater in the 
North and Northeast of Brazil (9.3 ± 2.3%) and lower in 
the Southeast (8.8 ± 2.0%), p = 0.003, and in both regions 
levels of HbA1c was significantly related to severity of 
DR, p < 0.012.
Hypertension was higher in the South, p = 0.000, and 
was related to severity of DR in all regions of Brazil, as 
was hypercholesterolemia, exception made for the Mid-
west region. Prevalence of hypercholesterolemia was 
higher in the Southeast, p = 0.000. Whereas, prevalence 
of smokers where proportionally higher in the South, 
p = 0.000.
Regarding the economic status, the Midwest region 
concentrated the highest proportion of high economic 
status, the South and Southeast, the medium economic 
status and the North and Northeast, the low and very low 
economic status, p = 0.000.
Concerning level of care, in the Southeast the sec-
ondary level of care had greater frequency of moderate 
NPDR, and the tertiary level of care, PDR. In the North 
and Northeast, the secondary level of care accounted for 
higher frequency of mild NPDR and PDR, whereas, the 
tertiary level of care had greater frequency of absence of 
DR, p = 0.000.
Southeast
In the Southeast, patients with moderate NPDR had 
grater BMI then those with the absence of DR (26.3 ± 4.9 
vs 24.0 ± 3.9), p = 0.002. Level of HbA1c was lower in the 
absence of DR when compared to mild NPDR (8.7 ± 2.0 
vs 9.3 ± 2.2%), p < 0.023. Hypercholesterolemia was sig-
nificantly related to moderate NPDR, p = 0.000 and the 
proportion of smokers was higher in PDR, p = 0.048.
South
In the South, patients with mild DR had higher BMI than 
those with the absence of DR (26.0 ± 2.8 vs 23.9 ± 4.0), 
p = 0.004. Hypercholesterolemia was significantly related 
to PDR, p = 0.009.
North and Northeast
In the North and Northeast level of HbA1c was higher in 
moderate NPDR when compared to absence of DR and 
mild NPDR (11.1 ± 2.5 vs 9.0 ± 2.1 and 9.1 ± 2.3%, respec-
tively), p < 0.005. Hypercholesterolemia was significantly 
related to moderate NPDR and PDR, p = 0.000. Level of 
education was lower in moderate NPDR, 10.0 ± 3.7 years 
of study, when compared to absent DR, 12.7 ± 3.9 years of 
study, p < 0.005. More cases of absent DR were identified 
in the medium economic status, 110 (33.2%), S.Res. 2.8, 
as was PDR in the low and very low economic status, 29 
(72.5%) and 6 (15.0%), respectively, S.Res. 1.8, p = 0.0439.
Midwest
In the Midwest region patients with PDR had higher 
BMI than those with absent DR (25.8 ± 4.5 vs 23.1 ± 4.2), 
p = 0.010.
Multinomial regression and stepwise multivariate analysis 
for NPDR
Multinomial regression and stepwise analyses (Table  4) 
showed that duration of diabetes and level of HbA1c was 
significantly related to NPDR in all geographic regions. 
Hypertension was also statistically significant in the 
Southeast (2.4, IC 95% of 1.5–3.9, p = 0.000) and North 
and Northeast (2.4, IC 95% of 1.1–5.3, p = 0.028) of Bra-
zil, whereas BMI was in the South (1.1, IC 95% of 1.0–1.2, 
p = 0.024). In the Midwest, the odds of NPDR was asso-
ciated with Caucasian ethnicity (2.8, IC 95% of 1.3–6.1, 
p = 0.012).
Multinomial regression and stepwise multivariate analysis 
for PDR
Considering PDR, multinomial regression and stepwise 
analyses reveled statistical significance for duration of 
DM in every geographic region and hypertension in the 
Southeast, South and North and Northeast. On the other 
hand, high and medium economic status (0.2, IC 95% of 
0.1–0.5, p = 0.002) lowered the risk of proliferative DR in 
the North and Northeast as did physical activity in the 
Southeast (0.6, IC 95% of 0.3–1.0, p = 0.043).
Analysis of variables related to DME by geographic regions
Analysis of variables related to DME by geographic 
regions of Brazil are shown in Table 5.
Longer duration of diabetes was significantly related 
to the presence of DME in the Southeast and Midwest 
regions (19.8 ± 7.5 vs 16.7 ± 9.7  years, p = 0.047, and 
24.9 ± 10.3 vs 13.3 ± 8.2  years, p = 0.000, respectively). 
Higher level of HbA1c only correlated to the presence 
of DME in the North and Northeast of Brazil (12.0 ± 3.1 
vs 9.2 ± 2.2%, p = 0.009). Still in the North and North-
east, the presence of DME was greater among very low 
economic status (40.0% vs 7.3%, p = 0.016). In the South, 
patients who reported physical activity had lower prev-
alence of DME (5.3% vs 94.7%, p = 0.014). Hyperten-
sion was positively related to the presence of DME in 
the Southeast and Midwest regions (7.1%, p = 0.000 and 
17.6%, p = 0.016). Hypercholesterolemia was only signifi-
cantly related to DME in the Southeast (5.3%, p = 0.013).
After, multinomial regression and stepwise analyses, 
the variables that reached statistical significance was 
hypertension in the Southeast (5.6, IC 95% of 2.2–14.4, 
p = 0.000), HbA1c in the North and Northeast (1.5, IC 
95% of 1.2–2.0, p = 0.001) and duration of diabetes in the 
Midwest (1.1, IC 95% of 1.1–1.2, p = 0.000). Model was 
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not applied in the South because of the limited number 
of cases of DME.
Multinomial regression and stepwise multivariate analysis 
for NPDR, PDR and DME with region as independent 
variable
When multinomial regression was applied, and region 
was considered an independent variable, prevalence of 
NPDR was not statistically different in each geographic 
region, on the other hand, in the Midwest, prevalence of 
PDR (2.4, IC 95% of 1.1–5.1, p = 0.022), and DME (7.4, IC 
95% of 2.0–27.6, p = 0.003) was significantly higher.
Discussion
Data on the prevalence of DR will vary according to 
study methodology, clinic and demographic data of the 
participants, this fact, combined with the diverse social 
and cultural reality of the five geographic regions of Bra-
zil, reflects the overall results presented by this study. 
The North and Northeast at initial analyses had lower 
prevalence of DR as they had lower mean duration of 
diabetes. On the other hand, the South had higher preva-
lence of PDR as they had greater mean duration of DM 
as well as higher prevalence of hypertension. Adjusting 
our model to investigate actual differences in the preva-
lence of DR between the five geographic regions of Brazil, 
we found no variation in the matter of NPDR. However, 
the Midwest region concentrated more severe cases of 
this pathology, as the prevalence of PDR and DME was 
higher in this part of Brazil independently of every other 
risk factor, age, sex, ethnicity, level of education, eco-
nomic status, duration of diabetes, HbA1c, BMI, level of 
exercise, smoking, hypertension, hypercholesterolemia 
and level of care. What leads to a more severe DR in 
patients with T1D in the Midwest region has yet to be 
enlightened.
As a country with continental territory, racial and cul-
tural miscegenation, Brazil experiences great social eco-
nomic problems such as social inequality. The human 
development index (HDI) revels profound differences 
within the country. The Brazilian Federal District, located 
at the Midwest region, has the highest HDI, 0.839, con-
sidered a very high index. On the other hand, the North 
and Northeast has half of its counties leveled at a medium 
HDI, with index as low as 0.667 in 2014, not to mention 
level of education, reflecting levels of low HDI in two of 
its counties [15]. Other than economic and social devel-
opment differences, cultural habits that differ in each of 
Table 4 Final adjusted stepwise analysis with diabetic retinopathy as dependent variable
DR diabetic retinopathy, BMI body mass index
Non-proliferative DR Proliferative DR
O.R CI 95% p value O.R CI 95% p value
Southeast
 Duration of diabetes, years 1.1 1.0 1.1 0.000 1.1 1.1 1.2 0.000
 HbA1c (%) 1.3 1.2 1.4 0.000 1.2 1.0 1.4 0.058
 BMI 1.0 1.0 1.1 0.155 1.1 1.0 1.1 0.080
 Hypertension 2.4 1.5 3.9 0.000 3.5 1.8 6.6 0.000
 Physical activity 0.7 0.5 0.9 0.020 0.6 0.3 1.0 0.040
South
 Duration of diabetes, years 1.1 1.0 1.1 0.002 1.1 1.1 1.2 0.000
 HbA1c (%) 1.4 1.1 1.7 0.001 1.1 0.9 1.5 0.318
 BMI 1.1 1.0 1.2 0.024 1.0 0.9 1.2 0.980
 Hypertension 1.3 0.5 3.2 0.628 5.7 1.9 17.5 0.002
 Physical activity 1.7 0.8 3.5 0.154 2.5 0.9 6.7 0.076
North and Northeast
 Duration of diabetes, years 1.1 1.0 1.1 0.001 1.2 1.1 1.3 0.000
 HbA1c (%) 1.2 1.1 1.4 0.001 1.2 1.0 1.4 0.041
 BMI 1.1 1.0 1.1 0.221 0.9 0.8 1.0 0.063
 Hypertension 2.4 1.1 5.3 0.028 5.5 2.1 14.8 0.001
 Economic status 0.6 0.4 1.1 0.126 0.2 0.1 0.5 0.002
Midwest
 Duration of diabetes, years 1.1 1.1 1.3 0.000 1.3 1.2 1.4 0.000
 HbA1c (%) 1.3 1.1 1.6 0.014 1.3 1.0 1.8 0.084
 Caucasian 2.8 1.3 6.1 0.012 0.5 0.2 1.6 0.262
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the five regions of Brazil may influence risk factors for 
chronic diseases, and therefore severity of DR, related to 
eating habits and lifestyle [16]. This combination of reali-
ties generates a complex and multifactorial panorama, 
that challenges health approach in Brazil.
The prevalence of any DR and PDR in each geographic 
region of Brazil correlates with the prevalence esti-
mated from a pooled meta-analysis in patients with T1D 
[17], which varied from 20.53 to 0.37%, respectively, in 
patients with less than 10 years duration of DM to 55.55 
and 19.46%, respectively, in patients with DM duration 
between 10 and less than 20 years. In the meta-analysis 
above mentioned, prevalence of DME in patients with 
T1D and duration of diabetes between 10 and less than 
20 years was 12.27%. In our study, prevalence of DME in 
the Midwest region of Brazil more closely correlates to 
the global estimates, but prevalence of maculopathy in 
the South, Southeast and North and Northeast was lower 
than expected.
As presumed and vastly proven [18, 19], time of diabe-
tes in our study was directly related to the presence and 
severity of DR in all studied regions and to DME in the 
Southeast and Midwest. These results reinforce the role 
of duration of diabetes as a major risk factor in the devel-
opment and severity of DR.
In every geographic region, the glycemic control was 
an independent variable in the development of DR in our 
study, fact proven since the DCCT and by several other 
studies, highlighting the HbA1c as a major modifiable 
risk factor [20–23]. Non of the studied regions achieved 
mean HbA1c within the recommended level for adequate 
clinical and metabolic control established by the Brazil-
ian Diabetes Society and ADA [9, 24] and only the South-
east achieved mean levels lower to 9.0%, that defines poor 
glycemic control. We emphasize the special attention the 
glycemic control deserves in the North and Northeast 
of Brazil, since patients presented higher mean levels of 
HbA1c and glycemic control was an independent risk 
factor for DME.
A positive relation between DR and hypertension has 
been constantly demonstrated [25–27]. Prevalence of 
hypertension was higher in the South, where the risk of 
PDR was 5 times higher in the presence of hypertension 
as was the risk of DME in the Southeast. As a well-known 
major modifiable risk factor in the development and 
severity of DR, hypertension proved to play an impor-
tant role in DR in the South, Southeast and North and 
Northeast of Brazil. Hypercholesterolemia was related to 
the presence and severity of DR in the South, Southeast 
and North and Northeast but had no strength as an inde-
pendent factor.
BMI is still not clearly linked to the presence and sever-
ity of DR in patients with T1D. In our study, overweight 
Table 5 Clinic and laboratory data for diabetic macular 
edema by geographic region
Data are presented as the means (SD) and N (%)
BMI body mass index
a Standard Residual 3.9, b Standard Residual 2.8
Variables Diabetic macular edema p value
Yes No
Duration of diabetes, years
Mean (SD)
 Southeast 19.8 ± 7.5 16.7 ± 9.7 0.047
 South 28.7 ± 8.3 17.4 ± 9.9 0.059
 North and Northeast 15.0 ± 8.0 12.5 ± 7.7 0.276
 Midwest 24.9 ± 10.3 13.3 ± 8.2 0.000
Level of HbA1c (%)
Mean (SD)
 Southeast 9.6 ± 2.9 8.8 ± 2.0 0.328
 South 10.5 ± 3.3 9.0 ± 2.1 0.059
 North and Northeast 12.0 ± 3.1 9.2 ± 2.2 0.009
 Midwest 8.8 ± 1.7 9.1 ± 2.1 0.658
BMI
Mean (SD)
 Southeast 25.4 ± 4.0 24.5 ± 4.5 0.250
 South 25.5 ± 0.8 24.5 ± 3.9 0.409
 North and Northeast 23.9 ± 2.8 23.5 ± 3.6 0.718
 Midwest 25.1 ± 5.0 23.8 ± 4.4 0.353
Hypertension
 Southeast
  Yes 10 (7.1%)a 130 (92.9%) 0.001
  No 9 (1.5%) 602 (98.5%)a
 South
  Yes 2 (3.5%) 55 (96.5%) 0.168
  No 1 (0.6%) 160 (99.4%)
 North and Northeast
  Yes 2 (3.5%) 55 (96.5%) 0.252
  No 6 (1.5%) 407 (98.5%)
 Midwest
  Yes 6 (17.6%)b 28 (82.4%) 0.016
  No 8 (4.7%) 161 (95.3%)b
Hypercholesterolemia
 Southeast
  Yes 10 (5.3%)b 180 (94.7%) 0.013
  No 9 (1.6%) 550 (75.3%)b
 South
  Yes 1 (2.0%) 48 (98.0%) 0.536
  No 2 (1.2%) 167 (98.8%)
 North and Northeast
  Yes 3 (4.1%) 71 (95.9%) 0.116
  No 5 (1.3%) 391 (98.7%)
 Midwest
  Yes 5 (13.2%) 33 (86.8%) 0.146
  No 9 (5.5%) 156 (94.5%)
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was noticed among those with NPDR in the Southeast 
and PDR in the Midwest region at a significant level and 
should be a factor to be observed. The roll of smoking is 
also controversy, but in our study the South and South-
east ought to be alert as smoking was a contributing fac-
tor to DR [28].
Our study shows the diverse economic reality of each 
geographic region and best correlates it with DR in the 
Northeast, where the high and medium economic status 
had 80% less chance of PDR and the prevalence of DME 
was higher in the very low economic status. Data from 
a National Survey in the five geographic regions of Bra-
zil showed that both the quality of health as the use of 
health services in the North and Northeast of Brazil were 
at significant lower levels when compared to the other 
geographic regions, South, Southeast and Midwest [29]. 
Substandard access to health care in this part of Brazil 
is a well known reality and will reflect in every aspect 
of the individual’s health combined with social inequal-
ity, where individuals at social vulnerability will have less 
access to the health care system, public or private.
In Brazil, the public health system is structured in three 
levels of care and patients should move from the first 
towards the third level of care according to disease com-
plexity. In the North and Northeast, the second level of 
health care concentrated higher frequency of PDR than 
the third level, which, in the other hand, concentrated 
higher frequency of absence of DR, an inversion of flow 
of how the public health system was designed to work 
in Brazil, where the tertiary level should account for the 
most severe cases and where the system is structured 
to deal with the complex treatment it will demand. As 
expected, our study revels signs of a public health care 
system better organized in the Southeast, where the ter-
tiary level of care accounted for more cases of PDR.
At last, independently of DR, the studied population 
presented other ophthalmological pathologies, such as 
cataract and glaucoma, what leads us to reinforce the 
essential role of regular ophthalmological examination as 
a routine in the health care of patients with DM.
To our knowledge, this is the first large sample size 
study that aims to study the prevalence of DR and its 
risk factors in each of the five geographic regions of Bra-
zil. With only patients with T1D, represents the diverse 
young T1D population of Brazil, with a wide range of 
ethnic groups and economic backgrounds from all geo-
graphic regions of the country. This constitutes the pri-
mary strength of this study.
Our study has some limitations that must be men-
tioned. The first one would be the classification of DME 
without slit lamp examination, which could have under-
estimated the prevalence of maculopathy in our results. 
Since retinopathy classification was not stated by the 
same examiner it could be listed as a limitation although 
they were all performed by retina specialist with com-
bined training in the same university center. The lower 
number of participants at the North of Brazil led us to 
combine data with the Northeast, this fact limits our 
analysis to distinguish prevalence of DR in these two 
important geographic region of Brazil. The diagnoses of 
DM at clinical bases could also be stated as a limitation.
Conclusions
We conclude that the prevalence of NPDR in patients 
with T1D was no different between each geographic 
region of Brazil. Furthermore, a higher prevalence of 
PDR and DME, which are considered as sight threatening 
stages of the disease, was noticed in the Midwest region 
and deserves further investigations by other studies. 
Duration of DM is of central importance to all, as is gly-
cemic control, that should receive better effort to have its 
level lowered by every geographic region, particularly at 
the North and Northeast. Hypertension is another fun-
damental factor to every region, at special in the South 
and Southeast. Finally, patients in social and economic 
vulnerability deserves special attention in the North and 
Northeast of Brazil.
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